3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
3
Neoplasm Metastasis
2
Thrombocytosis
1
Recurrence
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Breast Cancer With Intracranial Metastases
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Brain Neoplasms
1
Blast Crisis
1
Anemia
1
Interventions
Trastuzumab
18
Radiosurgery
15
Capecitabine
13
Lapatinib
11
Radiotherapy
9
Magnetic Resonance Spectroscopy
9
trastuzumab deruxtecan
7
Temozolomide
6
tucatinib
4
pembrolizumab
4
paclitaxel-Angiopep-2 conjugate
4
eribulin
4
Vinorelbine
4
Specimen Handling
4
Paclitaxel
4
Methotrexate
4
Cisplatin
4
sacituzumab govitecan
3
pyrotinib
3
abemaciclib
3
Radiation
3
Fluorodeoxyglucose F18
3
pertuzumab
2
palbociclib
2
neratinib
2
durvalumab
2
cediranib
2
cabazitaxel
2
Sodium Chloride
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
XRP6258
×
Breast
×
Clear all
NCT02166658
2018-01-23
CaBaMet
AIO-Studien-gGmbH
Phase 2
Terminated
8 enrolled